Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
American Journal of Hematology
|
June 30, 2004
Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma
Semra Paydas, Melek Ergin, Kahraman Tanriverdi, et al.
Nuclear Medicine Communications
|
December 3, 2009
The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up
Zeynep Yapar, Mustafa Kibar, A Fuat Yapar, et al.
Oncoscience
|
August 6, 2015
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
Umut Disel, Alexis Germain, Bahar Yilmazel, et al.
Cancer Medicine
|
December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Deniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 2, 2022
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
Caicun Zhou, Dingzhi Huang, Yun Fan, et al.
Advances in Therapy
|
March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Markus Moehler, Do-Youn Oh, Ken Kato, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
BMJ (Clinical Research Ed.)
|
May 28, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
American Journal of Hematology
|
June 30, 2004
Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma
Semra Paydas, Melek Ergin, Kahraman Tanriverdi, et al.
Nuclear Medicine Communications
|
December 3, 2009
The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up
Zeynep Yapar, Mustafa Kibar, A Fuat Yapar, et al.
Oncoscience
|
August 6, 2015
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
Umut Disel, Alexis Germain, Bahar Yilmazel, et al.
Cancer Medicine
|
December 23, 2023
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study
Deniz Can Guven, Musa Baris Aykan, Harun Muglu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 2, 2022
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
Caicun Zhou, Dingzhi Huang, Yun Fan, et al.
Advances in Therapy
|
March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Markus Moehler, Do-Youn Oh, Ken Kato, et al.
Cancers
|
June 27, 2024
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
Yasin Kutlu, Shute Ailia Dae, Feride Yilmaz, et al.
Scientific Reports
|
July 13, 2025
Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
Maral Martin Mildanoglu, Yasin Kutlu, Onur Bas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
BMJ (Clinical Research Ed.)
|
May 28, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, et al.
Page
of 5